ARTICLE | Company News
GSK, Gilead, Shire gain RDPAC membership
September 26, 2017 11:30 PM UTC
China’s R&D-based Pharmaceutical Association Committee (RDPAC) approved new member applications from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), Gilead Sciences Inc. (NASDAQ:GILD) and Shire plc (LSE:SHP; NASDAQ:SHPG).
In 2013, media outlets reported that GSK voluntarily withdrew its membership from RDPAC following allegations of bribery in China. That year, China's Ministry of Public Security arrested several GSK executives after finding evidence they had bribed government officials, foundations, hospitals and doctors (see BioCentury Extra, July 11, 2013; July 24, 2013 & Sept. 9, 2013)...